Explore › Finding
Finding null
Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Youth MASC. All other youth-report pairwise comparisons on anxiety symptoms, anxiety impact, and depressive symptoms were not statistically significant at week 12 or week 36.
Effect sizeb= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)
Follow-up12 weeks
ComparatorPill placebo and comparisons among active treatments
Effect summarynull; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

Connected entities

Interventions
Cbt protein, Drosophila
Conditions
Anxiety Disorders
Outcomes
anxiety symptoms and depressive symptoms
Populations
Children

Source

PMC6425733
Secondary Outcomes From the Child/Adolescent Anxiety Multimodal Study: Implications for Clinical Practice
Read on PMC → · View in graph →